Scarica l'app Stockscreener
1.36
5.56%
-0.08
Dopo l'orario di chiusura:
1.28
-0.08
-5.88%
Precedente Chiudi:
$1.44
Aprire:
$1.43
Volume 24 ore:
348.22K
Relative Volume:
0.39
Capitalizzazione di mercato:
$132.04M
Reddito:
-
Utile/perdita netta:
$-13.73M
Rapporto P/E:
-10.46
EPS:
-0.13
Flusso di cassa netto:
$-3.92M
1 W Prestazione:
+27.10%
1M Prestazione:
+10.57%
6M Prestazione:
+37.33%
1 anno Prestazione:
+61.69%
Intervallo 1D:
$1.29
$1.43
Intervallo di 1 settimana:
$1.01
$1.53
Portata 52W:
$0.5437
$1.91
Tiziana Life Sciences Ltd Stock (TLSA) Company Profile
Nome
Tiziana Life Sciences Ltd
Settore
Industria
Telefono
-
Indirizzo
-
Confronta TLSA con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
TLSA
Tiziana Life Sciences Ltd
|
1.36 | 132.04M | 0 | -13.73M | -3.92M | -0.13 |
|
VRTX
Vertex Pharmaceuticals Inc
|
493.84 | 122.76B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
602.64 | 61.38B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
614.76 | 36.37B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
251.56 | 30.12B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
244.90 | 24.70B | 3.81B | -644.79M | -669.77M | -6.24 |
Tiziana Life Sciences Ltd Stock (TLSA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2020-12-22 | Iniziato | B. Riley Securities | Buy |
| 2018-12-17 | Iniziato | Laidlaw | Buy |
Tiziana Life Sciences Ltd Borsa (TLSA) Ultime notizie
Dosing begins in Tiziana Life Sciences’ trial of foralumab for na-SPMS - Yahoo Finance
How to interpret Tiziana Life Sciences Ltd (TLSA)’s stock chart patterns - uspostnews.com
Tiziana Life Sciences Ltd: A Comprehensive Look at the Stock’s Ups and Downs - investchronicle.com
Small cap wrap: Tiziana Life Sciences, Excellon Resources, Lancaster Resources... - Proactive Investors
Tiziana Life Sciences Announces University of Massachusetts Starts Dosing Intranasal Foralumab in Phase 2 Multiple Sclerosis Trial - marketscreener.com
Tiziana Life Sciences Announces University of Massachusetts Commences Dosing Intranasal Foralumab in Phase 2 Multiple Sclerosis Trial - The Manila Times
Breakthrough MS Treatment Trial: UMass Joins Harvard, Yale, Johns Hopkins Testing Home-Use Nasal Drug - Stock Titan
Tiziana Life Sciences Announces University of Massachusetts Commences Dosing Intranasal Foralumab in Phase 2… - Informazione.it
Tiziana Life Sciences announces patient dosing in Phase 2 MS trial - Proactive financial news
Multiple sclerosis Pipeline Analysis and Clinical Trials - openPR.com
TLSATiziana Life Sciences Ltd Com Latest Stock News & Market Updates - Stock Titan
Small cap wrap: Zero Candida, Midnight Sun Mining, Tiziana Life Sciences, Trust Stamp... - Proactive financial news
Tiziana Life Sciences begins patient dosing in Phase 2 MS trial at Johns Hopkins - Proactive financial news
Tiziana Life Sciences Announces Johns Hopkins University Commences Dosing Nasal Foralumab In Phase 2 Multiple Sclerosis Clinical Trial - MarketScreener
Tiziana Life Sciences Announces Johns Hopkins University Commences Dosing Nasal Foralumab in Phase 2 Multiple Sclerosis Clinical Trial - The Manila Times
Major Breakthrough: Johns Hopkins Launches Novel Nasal Treatment in Phase 2 MS Trial - Stock Titan
Tiziana Life Sciences begins dosing in trial of therapy for multiple sclerosis - Yahoo Finance
Tiziana Life Sciences begins dosing in Phase 2 trial for intranasal foralumab in SPMS - Proactive financial news
Small cap wrap: Northern Superior Resources, Tiziana Life Sciences, Alternus Clean Energy... - Proactive Investors
Multiple sclerosis Clinical Trials and Studies 2025: EMA, PDMA, - openPR
Tiziana Life Sciences Announces Yale University Commences Intranasal Foralumab Dosing in Phase 2 Multiple Sclerosis Trial - The Manila Times
Yale Launches Groundbreaking Intranasal MS Treatment Trial: Tiziana's Innovation in Focus - Stock Titan
Tiziana Life Sciences Ltd Files For Mixed Shelf Of Up To $250 MillionSEC Filing -March 24, 2025 at 05:22 pm EDT - Marketscreener.com
Tiziana Life Sciences CEO to present at 37th Annual ROTH Conference - Proactive Investors UK
Tiziana Life Sciences to Present at the 37th Annual Roth Conference - The Manila Times
Tiziana Life Sciences Reveals Growth Strategy at Major ROTH ConferenceKey Updates Expected - StockTitan
Tiziana Life Sciences Regains Compliance with Nasdaq Listing Minimum Bid Price Rule - The Manila Times
Tiziana Life Sciences Regains Compliance with Nasdaq Listing Requirements - Nasdaq
Tiziana Life Sciences Regains Compliance With Nasdaq Listing Minimum Bid Price Rule - MENAFN.COM
Tiziana Life Sciences Dodges Delisting: How Company Saved Its Nasdaq Status - Stock Titan
Oramed Pharmaceuticals And 2 Other Penny Stocks With Promising Potential - Simply Wall St
Tiziana Life Sciences Announces TV Interview with First Patient Dosed with Moderate Alzheimer's Disease - Informazione.it
Can Tiziana's Foralumab Enable Breakthroughs In Neuroinflammatory And Neurodegenerative Diseases? - RTTNews
Tiziana Life Sciences stock soars to 52-week high of $1.75 - Investing.com
Democrat-led states join legal fight over Trump's mass firings of federal workers -March 06, 2025 at 10:38 pm EST - Marketscreener.com
Tiziana Life Sciences Ltd. (NASDAQ: TLSA) Stock Hits Multi-Month High After Filing a Key IND with the FDA - DRP Journal
Tiziana: Foralumab Drug Development Presses On With Additional EAP Enrollment - Seeking Alpha
Sector Update: Health Care -March 04, 2025 at 03:39 pm EST - Marketscreener.com
Tiziana submits FDA investigational new drug application - Proactive Investors UK
Tiziana Life Sciences Files New Drug Application for ALS Drug Candidate -March 04, 2025 at 09:03 am EST - Marketscreener.com
Tiziana Life Sciences Advances ALS Treatment with FDA IND Submission - TipRanks
Tiziana Life Sciences Files Investigational New Drug Application With FDA For ALS Phase 2 Clinical Trial - Marketscreener.com
Tiziana Life Sciences Files Investigational New Drug Application with FDA for ALS Phase 2 Clinical Trial - The Manila Times
Could This Intranasal Therapy Change ALS Treatment? Tiziana Seeks FDA Approval - StockTitan
Tiziana Life Sciences Ltd (NASDAQ:TLSA) Sees Significant Drop in Short Interest - Defense World
AIM ImmunoTech, PepGen, Aeon, Tiziana, Moleculin: 5 Biotech Stocks That Led Retail Message Growth Last Week - MSN
Why Tiziana Life Sciences Ltd (TLSA) is Skyrocketing So Far in 2025 - Insider Monkey
Why These 15 Biotech Stocks Are Skyrocketing So Far In 2025 - Insider Monkey
Tiziana stock jumps 12% on TBI drug study publication - MSN
Tiziana Life Sciences' lead candidate demonstrates favorable safety profile and clinical response - Proactive Investors UK
Market movers: Ideal Power, Tiziana Life Sciences, Medicus Pharma... - Proactive financial news
Tiziana Life Sciences Ltd Azioni (TLSA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.24%
36.06%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):